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HIV-1 controllers are patients who control HIV-1 viral replication without antiretroviral therapy. Control is
achieved very early in the course of infection, but the mechanisms through which viral replication is restricted
are not fully understood. We describe a patient who presented with acute HIV-1 infection and was found to
have an HIV-1 RNA level of b100 copies/mL. She did not have any known protective HLA alleles, but signiﬁcant
immune activation of CD8+ T cells and natural killer (NK) cells was present, and both cell types inhibited viral
replication. Virus cultured from this patient replicated aswell in vitro as virus isolated fromher partner, a patient
with AIDS who was the source of transmission. Virologic breakthrough occurred 9 months after her initial pre-
sentation and was associated with an increase in CD4+ T cell activation levels and a signiﬁcant decrease in NK
cell inhibitory capacity. Remarkably, CD8+ T cell inhibitory capacity was preserved and there were no new es-
cape mutations in targeted Gag epitopes. These ﬁndings suggest that fully replication-competent virus can be
controlled in acute HIV-1 infection in some patients without protective HLA alleles and that NK cell responses
may contribute to this early control of viral replication.
© 2017 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
Natural control of HIV-1 infection occurs in a small percentage of pa-
tients (Deeks and Walker, 2007; O'Connell et al., 2009a; Migueles and
Connors, 2010). While there have been many studies analyzing HIV-1-
speciﬁc CD8+ T cell mediated immune responses (Migueles et al.,
2002; Betts et al., 2006; Sáez-Cirión et al., 2007; Migueles et al., 2008;
Hersperger et al., 2010; Walker-Sperling et al., 2014; Migueles et al.,
2014) and viral ﬁtness (Blankson et al., 2007; Lamine et al., 2007;
Bailey et al., 2008; Miura et al., 2009; Buckheit et al., 2012; Noel et al.,
2016) in these patients, few studies have examined either parameter
during the acute and early phase of HIV-1 infection (Bailey et al.,
2007;Miura et al., 2010; Kuang et al., 2014; Yue et al., 2015). These stud-
ies have suggested that control is achieved shortly after HIV-1 infection
(Goujard et al., 2009), and that virologic escape is seen even when
relative control of viral replication is sustained (Goonetilleke et al.,
2009; Durand et al., 2010). Studies have also suggested that viral iso-
lates from recently infected HIV-1 controllers have reduced viral ﬁtness
potentially because of escape mutations and/or drug resistance muta-
tions (Miura et al., 2010). However, ﬁtness of recently transmitted
HIV-1 isolates has not been compared to ﬁtness of isolates obtained
from the transmitting partners. Furthermore, while ELISpot analyses
have been used to identify epitopes targeted during HIV-1 infection, a
qualitative analysis of these responses has not been performed. NK
cells play a role in innate immune responses, but their role in early con-
trol of viral replication in HIV-1 controllers has not been deﬁned. In this
study, we examined the suppressive capacity of CD8+ T cells and of NK
cells from an HIV-1 controller shortly after she presented with acute
HIV-infection. We also isolated virus, performed full genome sequence
analysis, and compared the genotype and phenotype of her HIV-1
virus to HIV-1 virus isolated from the partner who transmitted the
virus to her. In addition, we examined immune activation and inﬂam-
mation by ﬂow cytometry and plasma cytokine analysis. The patient
eventually developed breakthrough viremia, which enabled a
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comparison of her immunologic and virologic proﬁles before and after
the loss of elite control. The results further our understanding of the
spontaneous control of HIV-1 infection.
2. Materials and Methods
2.1. Subjects
Blood samples were obtained from the following subjects:
AC1: The index patient who was diagnosed with acute HIV-1 infec-
tion and had HIV-1 RNA level b 100 copies/mL in the absence of an-
tiretroviral therapy (ART).
VP1: The HIV positive transmitting partner of AC1.
Acute progressors (APs): These were three acute seroconverters
with high HIV RNA levels who were not on ART.
Chronic progressors (CPs): Patients on suppressive ART regimens
with viral loads below b50 copies/mL.
HIV controllers: These were chronically infected HIV-1 positive pa-
tients who controlled HIV replication without ART. There were 2
groups of controllers: elite suppressors (ES) who maintained HIV-1
RNA levels of b50 copies/mL and viremic controllers (VC) who
maintained HIV RNA levels between 50 and 2000 copies/mL
Healthy donors (HDs): HIV-1 seronegative donors.
All subjects signed a written informed consent and samples were
handled according to a protocol approved by either The University of
Texas Health Science Center at Houston, McGovern Medical School,
Committee for the Protection of Human Subjects or by the Johns Hop-
kins University IRB.
2.2. Replication-competent Virus Isolation
PBMCswere isolated fromwhole blood via Ficoll-Paque. For each in-
dividual, CD4+ T cells isolated from the PBMCs by magnetic isolation
(CD4+ T Cell Isolation Kit, Miltenyi Biotech)were cultured as previous-
ly described (Blankson et al., 2007). On day 13, culture supernatants
were tested for the presence of HIV-1 p24 antigen with the Perkin
Elmer p24 ELISA kit.
2.3. Proviral and Replication-competent Viral Sequencing
DNA was isolated from cell samples obtained from either primary
PBMCs or the cells used to grow replication-competent virus from AC1
and VP1 with the Gentra Puregene Cell Kit (Qiagen) according to
manufacturer's protocol. Viral gene sequences were ampliﬁed via
nested PCR with Invitrogen High Fidelity Platinum Taq polymerase as
follows. Outer gag ampliﬁcation: 94 °C for 3 min; 34 cycles of 30 s at
94 °C, 30 s of 50 °C, and 2 min 30 s of 68 °C; 5 min at 68 °C followed
by a 4 °C hold (primers: 5′-GCGAGAGCGTCAGTATTAAGC, 3′-
TCTTTATCTAAGGGAACTGAAAAATATGCATC). Inner gag ampliﬁcation:
94 °C for 3 min; 34 cycles of 30 s at 94 °C, 30 s of 50 °C, and 1 min 45 s
of 68 °C; 5 min at 68 °C followed by a 4 °C hold (primers: 5′-
GGGAAAAAATTCGGTTAAGGCC, 3′-CGAGGGGTCGTTGCCAAAGA). nef
ampliﬁcations: 94 °C for 3 min; 34 cycles of 30 s at 94 °C, 30 s of 55 °C,
and 2 min of 68 °C; 5 min at 68 °C followed by a 4 °C hold (outer
primers: 5′-GTAGCTGAGGGGACAGATAGGGTTAT, 3′-GCACTCAA
GGCAAGCTTTATTGAGGC; inner primers: 5′-CGTCTAGAACATACCTAGA
AGAATAAGACAGG, 3′-CGGAATCCGTCCCCAGCGGAAAGTCCCTTGTA).
Inner PCR products were run on a 1% Agarose gel. The target bands
were cut out and puriﬁedwith theQIAquickGel Extraction Kit (Qiagen),
and the puriﬁed PCR products were then sequenced by Genewiz using
the appropriate gag or nef inner PCR primers noted above. Individual se-
quences were analyzed with CodonCode before alignment to the Gag
and Nef HIV-1 Consensus B gene sequences obtained from the Los
Alamos Database using BioEdit.
2.4. Phylogenetic Analysis
Trees and bootstrap values were inferred using the Maximum Like-
lihood method based on the Hasegawa-Kishino-Yaho model
(Hasegawa et al., 1985), gamma distributed with invariant sites
(HKY+G+I model) (gag) or the HKY+G model (nef). The trees with
the highest log likelihood are shown with branches drawn to scale. Ini-
tial tree(s) for the heuristic search were obtained automatically by ap-
plying Neighbor-Joining and BioNJ algorithms to a matrix of pairwise
distances estimated using the Maximum Composite Likelihood (MCL)
approach, and then selecting the topology with superior log likelihood
value. Analyses were implemented in the Mega6 program (http://
www.megasoftware.net). Reference sequences for the trees were
found using the Los Alamos National LaboratoryHIV Sequence Database
(http://hiv.lanl.gov) implementation of the BLAST algorithm,which uti-
lizes sequence data from GenBank to ﬁnd those sequences in the public
domain that are most similar to the query. Clade D reference sequences
were obtained from the HIV-1 subtype reference alignments on the Los
Alamos National Laboratory server for gag and nef.
2.5. Viral Growth Curves
One millilitre of supernatant recovered from the co-culture de-
scribed above (Proviral and Replication-competent Virus Isolation)
with the highest p24 concentration was ampliﬁed to generate a stock
of patient virus. Pre-stimulated CD4+ T cells from HIV-negative indi-
viduals were isolated from PBMCs and spinoculated at 1200 ×g and
37°C for 2 h with the three viral stocks obtained as described above
with 250 ng p24 per 1 × 106 cells. The cells werewashed prior to cultur-
ing 1 × 106 cells permL of STCM in triplicate in a 48-well plate for seven
days at 37 °C. Supernatant samples taken immediately after plating and
on days 3, 5, and 7 were then tested for p24 concentration with the
Perkin-Elmer p24 ELISA kit.
2.6. Whole Blood Activation Marker Analysis
Blood was collected in EDTA-containing tubes and incubated at
room temperature overnight. The next day whole blood stained with
the following antibody panel for 15 min at 4 °C: HLA-DR•PerCP-Cy5.5
(Biolegend catalog # 307629, RRID:AB_893575) CD16•FITC (BD Biosci-
ences catalog # 556618, RRID:AB_396490), CD56•FITC (BD Biosciences
catalog # 562794), CD38•APC (BD Biosciences catalog # 555462,
RRID:AB_398599), CD8•APC-H7 (BD Biosciences catalog # 560179,
RRID:AB_1645481), CD3•PacBlue (BD Biosciences catalog # 558117,
RRID:AB_397038), and CD4•BV605 (Biolegend catalog # 317438,
RRID:AB_11218995); all other antibodies were obtained from BD Bio-
sciences). Stained blood was then incubated at room temperature for
10 min in BD FACS Lysis Buffer at a 1:4 ratio of blood to buffer and
then washed three times with PBS before running the samples on a
BD FACSCanto II. Results were analyzed with FlowJo 10 (TreeStar).
2.7. Plasma Cytokine and Chemokine Analysis
Whole blood obtained from EDTA tubes were incubated overnight,
and Ficoll density centrifugation was performed the next day to obtain
plasma. Each plasma sample was subjected to a single free-thaw cycle
and tested for 17 distinct analytes. IL-18 was measured using the
human IL-18 ELISA kit (MBL). The assay was performed per the
manufacturer's recommendations. In brief, all samples were diluted
1:5 in assay buffer and reported as pg/mL. Data were acquired using a
SpectaMax M5 (Molecular Devices). The LLOQ of IL-18 in serum sam-
ples is 25 pg/mL. The Meso Scale Discovery (MSD) multiplex cytokine,
proinﬂammatory and chemokine assays were used to assess 16 addi-
tional analytes: IL12/23p40, IL-15, IL-16, IL-7, IFN-g, IL-10, IL-1b, IL-2,
IL-6, IL-8,TNF-a, Eotaxin, IP-10, MCP-1, MIP-1a, MIP-1b. The assay was
performed per the manufacturer's recommendations. Data were
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acquired on a SECTOR Imager 2400. Results were analyzed using Meso
Scale DiscoveryWorkbench software. The LLOQ is for each analyte is in-
dicated where data is shown.
2.8. Inhibition Assays
PBMCs were isolated via Ficoll density centrifugation. PBMCs were
then split to isolate CD8+ T cells and NK cells (Miltenyi Biotech), and
CD4+ T cells (Miltenyi Biotech) were subsequently isolated from
CD8+T cell depleted PBMCs. CD4+T cells (Miltenyi Biotech)were fur-
ther isolated from CD8+ T cell-depleted PBMCs. CD4+ T cells were
spinoculated (or mock spinoculated) with 50 ng of GFP-containing
pseudotyped virus at 30 °C for 2 h at 1200 ×g (O'Doherty et al., 2000).
These infected cells were immediately co-cultured with CD8+ T cells
or NK cells at 37 °C at a 1:1 ratio. Triplicates were performed in experi-
ments with cells from HIV controllers, but for AC1, replicates were not
performed because of the low number of cells available. Infection was
measured after 3 days of co-culture by GFP expression in CD3+
(BV421, BioLegend catalog # 317343, RRID:AB_2565848) CD8- (APC,
BioLegend, catalog # 344722, RRID:AB_2075388) cells by FACS
(FACSCanto II, Becton Dickinson) as previously described (Pohlmeyer
et al., 2013). The range of GFP positive cells present in wells without ef-
fector cells was 2.3 to 12.9% (median of 6.5%).
2.9. Antibody Avidity
Recency of infection was determined by measuring anti-HIV anti-
body avidity at two sequential time points (Wang and Lagakos, 2009).
Antibody avidity was measured using a modiﬁed Genetic Systems
HIV-1/HIV-2 PLUS O EIA (Bio-Rad Laboratories, Redmond, WA, USA)
ELISA. Each time pointwas tested in duplicate, with onewell containing
diethyl amine (DEA) solution and the other with buffer. The percent
avidity (Avidity Index, AI) was calculated for each sample by dividing
the optical density of the DEA-treated well by the optical density of
the non-treated well for the same sample and multiplying by 100
(Laeyendecker et al., 2015).
3. Results
3.1. Clinical History of Patient
AC1 presented to the emergency departmentwith a 3-day history of
painful cervical and retroauricular lymphadenopathy. She reported not
having had a fever, trauma or pet contact. HIV-1 testing resulted in a
positive fourth-generation ARCHITECT HIV Ag/Ab Combo (CMIA) test
and a negative Bio-Rad Multispot HIV-1/HIV-2 test. Seven days after
the onset of clinical signs, HIV-1 RNA levels were 51 copies/mL and
Western blot was indeterminate with positive bands at p24, p40, p51/
p55 with weak positivity at gp160. The Multispot HIV-1/HIV-2 test
turned positive on day 25 and the HIV-1 RNA levels remained low at
37 copies/mL. She continued to have a low viral burden 80 and
157 days after onset of clinical signs (26 and 85 copies/mL respectively),
but on day 280, the HIV-1 RNA level increased to 7320 copies/mL and a
month later it remained elevated at 7400 copies/mL. The levels of CD4+
T cells dropped from 928 cells/μL (37%) on day 25 to 114 cells/μL (9%)
day 315 after onset of clinical signs (Fig. 1). She started combination an-
tiretroviral therapy (cART) with lamivudine 300 mg daily and
dolutegravir 50 mg daily at this time as part of a clinical trial. The initial
diagnosis of acute HIV-1 infection was conﬁrmed by measurement of
the avidity of her HIV-speciﬁc antibodies using the Bio-Rad assay. On
day 33, she had an avidity index of 29.5, much lower than the index
seen in our cohort of chronically HIV-1 infected elite controllers or sup-
pressors (Wendel et al., 2013). The avidity index increased to 88 on day
280, which is more consistent with chronic HIV-1 infection.
3.2. Phylogenetic Analysis Reveals Source of Transmission
The patient had started a new relationship 4 months prior to the ED
visit and her partner, VP1, was found to be HIV-1 positive with levels of
CD4+ T cells of 14 cells/μL and HIV-1 RNA levels of 120,000 copies/mL.
His HIV-1 antibody index at the time was 95, which is consistent with
chronic HIV-1 infection. Therefore, it is unlikely that AC1 transmitted
the virus to him. In order to determine whether the two patients were
in fact a transmission pair, virus was cultured from their CD4+ T cells
on day 33 and full genome sequence was obtained as previously de-
scribed. As shown in Fig. 2, the nef genes from the 2 patients were
very similar. Phylogenetic analysis of the nef and gag demonstrated
that isolatesweremore closely related to each other than any other iso-
late reported in the Los Alamos HIV sequence database, strongly sug-
gesting that the patients were in fact a transmission pair (Fig. 3).
3.3. Viral Fitness Studies Suggest That Transmitted Virus was not
Attenuated
In order to determine whether a difference in viral ﬁtness could ex-
plain AC1's lowHIV-1 RNA levels, we compared the kinetics of viral rep-
lication of isolates obtained from the 2 patients aswell as froman isolate
obtained from an acute HIV-1 seroconverter who had very high HIV-1
RNA levels. There was no signiﬁcant difference in the rate of viral repli-
cation (Fig. 4). Drug resistancemutationswere seen in some recently in-
fected HIV-1 controllers and were shown to contribute to reduced
ﬁtness of the viral isolates (Miura et al., 2010). Our patient did have
themajorNNRTImutation K103N, and themajor protease inhibitormu-
tation, V82L, but the replicative capacity of a chimeric virus containing
AC1 RT and protease genes was 77% by the PhenoSense HIV Assay
(Monogram Biosciences, South San Francisco, CA). The median replica-
tive capacity of viruses with RT and protease genes ampliﬁed fromHIV-
1 isolates from untreated patients using this assay in a large study was
79% (Goetz et al., 2010); thus, the data suggest that reduced ﬁtness be-
cause of drug resistancemutationswas not amajor cause of HIV control
in this patient.
3.4. Host Factors Studies Reveal Protective KIR Alleles
HLA and KIR typing were performed on both patients. Interest-
ingly, AC1 did not have any known HLA alleles that traditionally
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Fig. 1.Clinical history of AC1. CD4+T cell count (red) and viral load (blue) over time, with
day 1 as onset of clinical symptoms.
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confer protection (Table 1). Both patients were positive for KIR3DS1
as well as speciﬁc KIR3DL1 alleles that are associated with slowly
progressive disease at a population level when inherited with HLA-
BW4-80-Ile alleles (Martin et al., 2002; Martin et al., 2007). Of
note, both patients had 1 HLA-BW4-80-Ile allele (HLA-B*3801 in
AC1, HLA-B*5201 in VP1).
3.5. Changes in InﬂammatoryMakers and CD4+T Cell ActivationWere As-
sociated With Viremic Breakthrough
We looked for signs of immune activation and found that AC1’s
CD4+ T cells had little immune activation until her viral load reached
7000 copies/mL (Fig. 5). By day 335, the frequency of HLA-DR+
Fig. 2. HIV-1 proviral and replication-competent Nef sequences. Nef amino acid sequence of replication competent (RC) and proviral (P) sequences from both VP1 and AC1 with time
relative to the ﬁrst clinic visit of AC1 aligned to the Consensus B sequence retrieved from the Los Alamos Database. The AC1 HIV-1 proviral sequence from D335 is post-loss of control.
All other sequences of AC1 are pre-loss of control.
99
0.02
99
0.01
ba
Fig. 3. Phylogenetic analysis of viral sequences obtained from AC1 and VP1. Maximum likelihood phylogenetic trees of nef (a) and gag (b) nucleotide sequences are shown. Sequences
ampliﬁed from replication-competent virus (circles) and provirus (squares) for AC1 (green) and VP1 (blue) are compared to the most homologous clade B sequences (branches
without symbols) in the Los Alamos Database. Sequences from cladeD (black squares) serve as an outgroup. Bootstrap values of the clades including AC1 andVP1 sequences are indicated.
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CD38+ CD4+ T cells was much higher than the frequency seen in
chronically infected HIV-1 controllers and patients on suppressive
cART regimens (CPs), and comparable to the frequency seen in VP1. In
contrast, a high frequency of her CD8+T cells andNK cellswere activat-
ed at days 47 and 157. Themagnitude of immune activation of both cell
types was comparable to that seen in the 3 viremic acute HIV-1
seroconverters and did not change substantially after her virologic
breakthrough (Fig. 5).
We next analyzed inﬂammatory cytokines and we found dramatic
increases in plasma levels of IP10, IFN-γ andMIP-1α following virologic
breakthrough. Interestingly, the levels present at days 47 and 157 were
lower than that seen in the 2 acute HIV-1 seroconverters (AP2 and AP3)
with high HIV-1 RNA levels (Fig. 6). Other markers including IL-1b, IL-2,
IL-6, IL-7, IL-8, IL-10, IL-12/23 p40, IL-15, IL-16, IL-18, Eotaxin, MCP-1,
and TNF-alpha were not dramatically elevated in AC1 compared to the
HDs or to chronically HIV-1 infected ES and CPs (Supplementary Figs.
1 and 2).
3.6. Changes in NK Cell but not CD8+ T Cell Inhibitory Capacity was Asso-
ciated With Viremic Breakthrough
We askedwhether immune escape could have contributed to the vi-
rologic breakthrough. ELISpot analysis on day 157,when the patient still
had low HIV-1 viremia, revealed that 3 epitopes were targeted in Gag
(Fig. 7) including an overlapping peptide that contained the previously
described HLA-B*38 restricted Gag epitope GL9 (193-201, Pereyra et al.,
2014). Bulk HIV-1 proviral sequence on days 33 and 335 suggests that
there was no evolution in the Gag epitopes following virologic break-
through (Fig. 7). Elispot analyses also revealed a response to pooled
Nef overlapping peptides, but we did not have enough PBMCs to map
individual epitopes. We therefore screened the Los Alamos Database
for potential epitopes that could be presented by the patient's MHC
Class I proteins. Polymorphisms were seen in 4 of these potential epi-
topes as shown in Supplementary Table 1.
We next examined the inhibitory capacity of CD8+ T cells and NK
cells fromAC1onday47. Autologous CD4+T cellswere isolated and in-
fected with GFP expressing pseudotyped virus in the presence or ab-
sence of CD8+ T cells or NK cells at an effector to target ratio of 1:1
and 1:2. The inhibitory responses were compared to those from an
acutely infected viremic progressor (AP4) and 12 chronically infected
HIV-1 controllers 4 of whom were negative for the protective HLA-
B*57/58 and HLA-B*27 alleles (Supplementary Table 2). At an effector
to target (E:T) ratio of 1:1, CD8+ T cells from AC1 on day 47 inhibited
viral replication by 57%, compared to a median suppression of 88% for
HLA-B*57/58 positive controllers and a median suppression of 85% for
HLA-B*57/58 negative controllers. This is consistent with our prior re-
sults on the suppressive capacity of ES CD8+ T cells (Pohlmeyer et al.,
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cells, and p24 production was measured for a week post-infection. The AC1 viral isolate
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HLA alleles and KIR3DS1 and KIR3DL1 alleles of patients AC1 and VP1. HLA-BW4-80-lle al-
leles are underlined.
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Fig. 5. Immune activation of CD4+ T cells, CD8+ T cells, and NK cells. Whole blood
incubated at room temperature overnight was stained for HLA-DR and CD38 in the
presence of T and NK cell markers. A) CD4+ T cell activation. B) CD8+ T cell activation.
C) NK Cell activation. HD = HIV-negative healthy donor (n = 16). CP = chronic
progressor (n = 11). ES = elite suppressor (n = 12). AP = acute progressors (3
recently infected patients with high viral loads). AC1c = time points for which AC1
controlled viremia. AC1v = time points for which AC1 had lost control of viremia.
Speciﬁc day post initial clinic visit is indicated in legend.
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2013; Salgado et al., 2011) and with studies showing that controller
CD8+ T cells are generally very effective at inhibiting viral replication
(Migueles et al., 2002; Betts et al., 2006; Sáez-Cirión et al., 2007;
Migueles et al., 2008; Hersperger et al., 2010; Walker-Sperling et al.,
2014; Migueles et al., 2014). At the same E:T ratio, NK cells from AC1
on day 47 inhibited suppression of GFP expression by 44%, an index
that was similar to the suppressive capacity of NK cells from HLA-
B*57/58 positive controllers (median of 34%), but much higher than
the median suppressive capacity of 0.3% induced by NK cells from
HLA-B*57/58 negative controllers. CD8+ T cells and NK cells from
more patients were analyzed at an E:T ratio of 1:2 and a similar pattern
was seen. NK cells from a patient with primary HIV infection and a high
viral load (AP4) had no suppressive capacity. Interestingly when the
suppression assaywas repeated on day 277when the patient had expe-
rienced a viremic breakthrough, there was no change in her CD8+ T-
cell inhibitory response but, there was a marked decline in her NK
cells response (Fig. 8).
4. Discussion
We present a case of spontaneous control of HIV-1 during acute in-
fection followed by loss of control within the ﬁrst year of infection.
Our study is limited by the fact that we do not have samples over the
4-month period when viremic breakthrough actually occurred, but we
were still able to perform a comprehensive analysis of the patient's im-
mune system before and after the loss of control of viral replication.
While prior reports have suggested that virus ampliﬁed from some
HIV controllers in early infection are attenuated (Miura et al., 2010;
Kuang et al., 2014; Yue et al., 2015), our study suggests that the virus
cultured from this patient at day 33 replicated as well as virus from
her partner who had HIV-1 RNA levels of 120,000 copies/mL. Interest-
ingly, a prior study has shown a correlation between HIV-1 RNA levels
of patients in primary infection and the viral load in transmitting part-
ners (Hecht et al., 2010). This suggests that in most cases, viral ﬁtness
of the transmitting partner drives the level of HIV viremia in the recipi-
ents. However, thiswas clearly not the casewith AC1who controlled vi-
remia in spite of high HIV-1 RNA levels in VP1. In fact, the HIV-1 RNA
levels fromVP1 are a log higher than theHIV-1 RNA levels of the patient
who transmitted an attenuated virus to a patientwhobecame a control-
ler in a prior study (Yue et al., 2015). While we have documented three
cases of transmission of HIV-1 between chronic progressors with high
viral loads and HIV controllers (Bailey et al., 2008; Buckheit et al.,
2012), the HIV-RNA levels of the chronic progressors at the time of
transmission were unknown. This case is unique as both AC1 and VP1
were studied at the time of primary infection of AC1. Furthermore, we
were able to compare the growth kinetics of virus isolated from the
index patient to that of virus isolated from the transmitting partner,
something that has not been done in prior studies in early and acute in-
fection of HIV controllers.Whilewe did not perform a competition assay
between the isolates, the results suggest the transmitted virus had a
similar level of ﬁtness as the virus isolated from her partner. The repli-
cative capacity of virus from AC1 also suggested that drug resistance
mutations did not lead to signiﬁcantly reduced viral ﬁtness. Taken to-
gether, the data imply that fully pathogenic HIV-1 virus can be con-
trolled in acute infection.
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Fig. 6. Loss of viral control leads to increased levels of IP-10, IFN-y and MIP1-α in the
serum. Serum from ﬁve healthy donors (HD), eight chronic progressors (CP), eight elite
suppressors (ES), and two acute progressors (AP) were tested. Chronic progressor 1
(VP1) was tested at one time point. Acute controller 1 (AC1) was tested at four time
points, two prior to loss of viremic control (AC1c: D50, D160) and two post loss of
viremic control (AC1v: D280, D335). All samples were tested using the MSD multiplex
and reported as pg/ml, the lower limit of quantiﬁcation (LLOQ) is indicated as a dotted
line for each analyte.
Fig. 7.Gag epitope evolution in AC1. Gag epitopes responded to by AC1 as determined by ELISpot are shown compared to the Consensus B sequence for Gag retrieved from the Los Alamos
Database. Proviral or replication-competent determination is indicated next to time post ﬁrst clinic visit. Replication-competent sequence is from before loss of control, and the proviral
sequence is from before (D50) and after (D335) the loss of control.
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Plasma IP-10 concentrations have been reported to be higher in HIV
controllers than healthy donors (Noel et al., 2014) and have been previ-
ously shown to correlate with progression rates in early HIV infection
(Liovat et al., 2012) and with rebound viremia following treatment in-
terruption (Simmons et al., 2013). Our ﬁndings suggest that similar pat-
ternsmay be seen when natural control of viral replication is lost, and a
recent study suggested that HIV-1 controllers with higher IP10 levels at
baseline were more likely to have clinical progression (Noel et al.,
2015). IFN-γ and MIP1-α plasma concentrations do not correlate with
disease progression in HIV infection (Roff et al., 2014; Hittinger et al.,
1998) and it is not clear why elevated levels of both cytokines were
present following virologic breakthrough.
The patient's CD4+T cell count dropped at a rate thatwould be con-
sistent with that of a rapid progressor. However, studies have shown
that rapid progression is usually associated with very high HIV-1 RNA
levels at baseline (Socías et al., 2011), whereas this patient had low to
undetectable HIV-1 RNA levels during primary infection. A marked in-
crease in CD4+ T cell activation was seen after progression occurred.
It's not clear whether this was a cause or consequence of progression,
but in a prior study, bacterial and viral infections were associated with
immunologic progression in HIV controllers (Noel et al., 2015).
We show that by day 47, the patient had developed a CD8+ T-cell
response that was able to inhibit viral replication. A recent study of hy-
peracute HIV-1 infection suggested that the high level of immune acti-
vation seen in these cells was a reﬂection of HIV-speciﬁc responses
(Ndhlovu et al., 2015). Our patient sustained high levels of immune ac-
tivation in spite of low level viremia as late as 157 days after the onset of
clinical signs, suggesting that her CD8+ T cells may have continued to
suppress viral replication over this period of time. Interestingly, this
suppressive response was maintained when the patient's HIV-1 RNA
levels increased to 7320 copies/mL. This relatively low level of viremia
is typically seen in controllers who develop viremic breakthrough
(Noel et al., 2015) and is possibly amanifestation of continued T cellme-
diated control of viral replication. No mutations were detected in 3
targeted Gag epitopes. This is consistent with studies in HLA-B*57 vire-
mic controllers where mutations in Gag epitopes did not correlate with
progression of disease (Durand et al., 2010).
The role of natural killer cells in elite control has not been fully
established (O'Connell et al., 2009b; Marras et al., 2013) and has not
been studied in primary HIV-1 infection in these patients. However,
the combined presence of HLA-BW4-80-Ile alleles and the NK cell re-
ceptor KIR3DS1 is associated with slow progression to AIDS (Martin
et al., 2002). A similar pattern is seen when HLA-BW4-80-Ile alleles
and speciﬁc KIR3DL1 alleles are present in patients (Martin et al.,
2007), and HIV-1 controllers who have both alleles have more robust
NK cell responses following type 1 interferon stimulation (Tomescu
et al., 2012). These data strongly suggest that NK cell responses contrib-
ute to the control of HIV-1 infection. AC1 was positive for KIR3DS1, the
protective KIR3DL1*015 allele, and an HLA-BW4-80-Ile allele (HLA-
B*3801). She also had NK cell activation and inhibitory NK cell re-
sponses at day 47, suggesting an important role of these cells in primary
infection. In contrast, NK cells from AP4 who had a viral load of 3.6 mil-
lion copies/mL in primary infection had a high level of immune activa-
tion but no viral suppressive capacity. Our data are consistent with
studies that have also shown marked activation of total and KIR-ex-
pressing NK cells in primary HIV-1 infection (Alter et al., 2009;
Naranbhai et al., 2013). These high activation levels were not present
in samples collected prior to infection and interestingly, therewas a sig-
niﬁcant decrease in cytotoxic responses of NK cells following infection
(Naranbhai et al., 2013). Similar impairment of NK cell cytotoxic
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responses have been seen in chronically infected viremic patients (De
Maria et al., 2003; Mavilio et al., 2003). The results may suggest that
NK cells from chronic progressors are initially able to control viral repli-
cation and eventually lose this capacity during primary infection,
whereas NK cells from HIV controllers maintain control of viral replica-
tion until the adaptive immune response is established. Longitudinal
analyses of NK cells from HIV-1 controllers and chronic progressors
will be needed to test this hypothesis.
Taken together, we present a comprehensive analysis of an HIV-1
controller in early infection. We studied viral ﬁtness, HIV-speciﬁc
CD8+ T cell responses, NK cell inhibitory responses, HIV-speciﬁc anti-
body avidity, immune activation, and plasma inﬂammatory markers.
The same responses were studied before and after virologic break-
through which enabled us to identify factors that were associated
with the loss of control of viral replication. Our data suggest that some
patients can control fully replication HIV-1 virus shortly after infection
even when protective HLA alleles are not present. AC1 had CD8+ T-
cell responses that were capable of inhibiting viral replication as early
as 50 days after the onset of clinical signs. Inhibitory NK cell responses
were also present at this time and may have helped to control viremia
prior to the development of the HIV-speciﬁc CD8+ T-cell response. It
is interesting that a reduction in this response was associated with
loss of virologic control. Further work will be needed to determine
whether this was a cause or consequence of virologic breakthrough.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ebiom.2017.01.034.
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